Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
高級檢索
  • Benefits of pain relief on fat...
  • 引用
  • 發送短信
  • 推薦此
  • 打印
  • 導出紀錄
    • 導出到 RefWorks
    • 導出到 EndNoteWeb
    • 導出到 EndNote
  • Permanent link
Benefits of pain relief on fatigue, function, and quality of life when joint inflammation is controlled in patients with RA

Benefits of pain relief on fatigue, function, and quality of life when joint inflammation is controlled in patients with RA

書目詳細資料
Main Authors: Van De Laar, M, Pope, J, Lee, Y, Fautrel, B, Ikeda, K, Quebe, A, Zhang, X, Gaich, C, De Leonardis, F, Lisse, J, Workman, J, Taylor, P
格式: Conference item
出版: BMJ Publishing Group 2019
  • 持有資料
  • 實物特徵
  • 相似書籍
  • 職員瀏覽
實物特徵
總結:

相似書籍

  • Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
    由: Fautrel, B, et al.
    出版: (2019)
  • Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
    由: Taylor, P, et al.
    出版: (2019)
  • Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
    由: Fautrel, B, et al.
    出版: (2017)
  • Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
    由: Taylor, P, et al.
    出版: (2019)
  • Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
    由: Fautrel, B, et al.
    出版: (2018)

檢索選項

  • 檢索歷史
  • 高級檢索

查找更多

  • 瀏覽目錄
  • 按字母順序瀏覽
  • Explore Channels
  • 課程儲備
  • 新項目

需要幫助?

  • 檢索技巧
  • 咨詢台
  • 常見問題